We read with interest the recent publication by Grazziutti et al. 1 on the incidence and risk factors of severe oral mucositis in myeloma patients undergoing melphalanbased stem cell transplantation. In that study, a standard melphalan dose of 200 mg/m 2 was given to the majority of patients (n ¼ 350), but a small number received a lower dose of 140 mg/m 2 , due to renal impairment (n ¼ 31). In the calculations of melphalan dose, actual body weight was used for patients weighing o60 kg and a calculated body weight was used for patients weighing X60 kg. The authors note that this method for dose determination resulted in wide variations in mg/kg melphalan dose (range: 2.4-6.2 mg/kg). High mg/kg melphalan dose and high serum creatinine concentration were both predictors of severe oral mucositis using multiple logistic regression analysis. Both of these factors may therefore be associated with high exposure to melphalan, but a pharmacokinetic analysis was not performed in this study. The authors note the requirement for further studies to understand better the interpatient variability in melphalan exposure and toxicity.
In a multi-institutional trial, we are currently undertaking such a study, researching the pharmacokinetics and pharmacodynamics of melphalan in myeloma patients receiving an autograft. To date, we have recruited 51 patients aged 38-73 years into our trial. A single melphalan dose of 200 mg/m 2 was administered to 29 patients, while the remaining 22 patients received lower doses (range: 115-193 mg/m 2 ) due to renal impairment or obesity. The dose was administered as an intravenous infusion over a median of 34 min. Our previously published high-performance liquid chromatographic method 2 was used to measure melphalan concentrations in 12 blood samples that were collected at 5, 10, 20, 30, 40 and 50 min and at 1, 2, 3, 4 and 8 h after the infusion end. Melphalan pharmacokinetic parameters, including clearance and area under the concentration versus time curve (AUC 0ÀN ) were then determined using the Kinetica software (Innaphase, Philadelphia, PA, USA). Patient clinical data, including weight and estimated glomerular filtration rate (eGFR), were tested for correlation with melphalan clearance. eGFR was estimated from plasma creatinine concentration, patient age and gender using the abbreviated MDRD equation 3 Figure 1) showing a tendency for high mg/kg dose to be associated with high exposure to melphalan. Clearance correlated positively with both weight (r ¼ 0.55, Po0.001, Figure 2 ) and eGFR (r ¼ 0.47, Po0.001). In patients older than 64 years (475th percentile, n ¼ 14) melphalan clearance was median 21.7 l/h (interquartile range: 20.5-30.1 l/h), which was significantly (Po0.05) lower than the median clearance of 30.8 l/h (interquartile range: 24.6-37.1 l/h) of younger patients (38-64 years, n ¼ 37) using the Mann -Whitney U-test, even though there was no significant difference in weight, eGFR or mg/kg dose. Therefore, lighter patients, the elderly and those with poor renal function tend to have low clearance and high exposure to melphalan for a given dose.
In conclusion, current methods for determining melphalan dose in myeloma lead to wide variability in exposure. This may impact on transplant outcome. Indeed, previous pharmacodynamic studies have related high melphalan exposure with prolonged platelet recovery time, the occurrence of gastrointestinal toxicity and severe myelosuppression. 4, 5 Improved methods of dose determination are required to ensure that patients in different clinical situations (for example, those who are obese, elderly or who have impaired renal function) achieve optimum levels of exposure. We are continuing to collect pharmacokinetic data as well as toxicity, efficacy and outcome data so that we can develop optimal dosing strategies for melphalan in myeloma. A population pharmacokinetic analysis will allow a comprehensive evaluation of the clinical factors that impact on melphalan pharmacokinetics and it may be possible to develop a nomogram that will aid in melphalan dosing. A detailed investigation of the relationship between melphalan exposure and transplant toxicity and efficacy will allow the identification of a target AUC 0ÀN range that is associated with a good outcome. 
